Frontlight ResearchEarly access
CompletedNo phase
Parent Artery Reconstruction for Cerebral Aneurysms Using a Novel Flow Diverter With Surface Modification
Key facts
- Who runs it
- Sinomed Neurovita Technology Inc.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 143 people enrolled
- Started
- 27 Mar 2023
- Ended
- 30 Aug 2024
- Type of study
- Interventional
- Treatments tested
- Cerebral flow diverter
- Record updated
- 13 July 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age 18 years to 75 years, male or non-pregnant female
- Unruptured wide-necked cerebral aneurysms confirmed by preoperative imaging (Wide-necked is defined as width ≥ 4 mm or a dome-to-neck ratio < 2)
- Parent vessel with a diameter range of 1.75-6.0 mm
- Those who voluntarily participate in the study and sign informed consent form
Who cannot take part
- Subject with target aneurysms are blood blister-like aneurysms, pseudoaneurysms, arteriovenous malformation, moyamoya disease-related aneurysm, or multiple aneurysms that cannot be treated with a single stent
- Subject with target aneurysm previously treated with craniotomy or other endovascular interventional therapy
- Known sensitivity to antiplatelet medications, anticoagulant medications, radiographic contrast agents, anesthetic, nickel, platinum-tungsten alloy, platinum-iridium alloy, and poly-N-[Tris(hydroxymethyl)methyl] acrylamide (poly-NTMA)
- Hospitalized surgical treatment within the previous 30 days or planned within the next 180 days after operation
- All subjects who are participating in other drug/medical device clinical trials and have not completed the programme requirements
- Severe respiratory system, liver and kidney diseases (such as creatinine ≥ 3.0 mg/dL (except dialysis)) or blood coagulation disorders before operation
- Platelet count is less than 100×109/L, international normalized ratio (INR) is more than 1.5
- Severe arteriosclerosis or tortuosity of intracranial artery, and the device is difficult to reach the target vessel
- Severe neurological deficit that renders the patient incapable of living independently (modified Rankin score ≥3)
- The survival expectation is less than 1 year
- Inapplicable for this study at the investigators' viewpoints
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The primary objective of this trial is to evaluate the safety and efficacy of the cerebral flow diverter in the endovascular treatment of wide-necked cerebral aneurysms
The group in the trial
- Cerebral flow diverterTreatment being tested
The cerebral flow diverter in the endovascular treatment of wide-necked cerebral aneurysms
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Multi-center, Single Arm Clinical Study to Evaluate the Safety and Effectiveness of the Flow Diverter Stent System in the Treatment of Cerebral Aneurysms
- Record updated
- 13 July 2026